Anti-amyloid treatments in Alzheimer's disease

Recent Patents on CNS Drug Discovery

Volumn 4, Issue 2, 2009, Pages 143-148

  Sapra, Mamta ^a   Kim, Kye Y ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Disease modifying; Immunotherapy; Secretase

Indexed keywords

ALPHA SECRETASE; AMYLOID ANTIBODY; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; ATORVASTATIN; BAPINEUZUMAB; BETA SECRETASE; CLIOQUINOL; COLOSTRININ; CURCUMIN; GAMMA SECRETASE; HUPERZINE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; PLACEBO; POLYPEPTIDE; PROTEIN ANTIBODY; ROSIGLITAZONE; SIMVASTATIN; TALSACLIDINE; UNCLASSIFIED DRUG; AMYLOID; AMYLOID BETA PROTEIN; ENZYME INHIBITOR;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNOTHERAPY; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL;

EID: 68849122813     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488909788453040     Document Type: Review

References (51)

1. Alzheimer's disease facts and figures. Alzheimer's Association home page. Available at: www.alz.org; 2008.
2. Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life, and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 17-28.
3. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; Issue 1: Art No. CD005593. DOI: 10. 1002/ 14651858. CD005593.
4. Reisberg B, Doody R, Stoeffler A, et al. Memantine in moderate-tosevere Alzheimer's disease. N Engl J Med 2003; 348: 1333-1341.
5. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in moderate to moderate Alzheimer's disease: A 24 week randomized controlled trial. Am J Geriatr Psychiatry 2006; 14: 704-715.
6. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: A randomized controlled trial. JAMA 2004; 291: 317-324.
7. Irie K, Murakami K, Masuda Y, et al. Structure of beta-amyloid fibrils and its relevance to their neurotoxicity: Implications for the pathogenesis of Alzheimer's disease. J Biosci Bioeng 2005; 99: 437-447.
8. Clippingdale AB, Wade JD, Barrow CJ. The amyloid-beta peptide and its role inAlzheimer's disease. J Pept Sci 2001; 7: 227-249.
9. Kang J, Lemaire H, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-736.
10. Ritchie CW, McLean C, Beyreuther K, et al. Role of beta amyloid in the pathogenesis of Alzheimer's disease. In: Burns A, O'Brien J, Ames D, Eds. Dementia. New York: Edward Arnold Publishers 2005; pp. 426-435.
11. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314: 777-784.
12. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
13. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
14. Selkoe DJ. Defining molecular targets to prevent Alzheimer's disease. Arch Neurol 2005; 62: 192-195.
15. Blumberg PM. Protein kinase C as the receptor for the phorbol ester tumor promoters. Cancer Res 1988; 48: 1-8.
16. Etcheberrigaray R, Tan M, Dewatcher I, et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 2004; 101: 11141-11146.
17. Mandel S, Weireb O, Amit T, et al. Mechanism of neuroprotective action of anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 2005; 48: 379-387.
18. Zhang HY, Yan H, Tang HC. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40)infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett 2004; 360(1-2): 21-24.
19. Hock C, Maddalena A, Hevser I, et al. Treatment with the selective muscarinic agonist Talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann N Y Acad Sci 2000; 920: 285-291
20. Pollack SJ, Lewis H. Secretase inhibitor for Alzheimer's disease: Challenges of a promiscuous protease. Curr Opin Investig Drugs 2005; 6: 35-47.
21. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the beta secretase inhibitor LY-411, 575 inhibits beta amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-12882.
22. Beher D, Clarke EE, Wrigley JD, et al. Selected non-steroidal antiinflammatory drugs and their derivatives target gamma-secretase at a novel site: Evidence for an allosteric mechanism. J Biol Chem 2004; 279: 43419-43426.
23. Netzer WJ, Dou F, Cai D, et al. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci USA 2003; 100: 12444-12449.
24. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer's disease. Neurology 2006; 66: 602-604.
25. Rosenberg RN. Metal chelation therapy for Alzheimer disease. Arch Neurol 2003; 60: 1678-1679.
26. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (Clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease. Arch Neurol 2003; 60: 1685-1691.
27. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-676.
28. Gibson Gl, Douraghi-Zadeh D, Parsons RB, Austen BM. Properties of ovine colostrinin(O-CLN) on the in vitro aggregation and toxicity of β-amyloid. Neurobiol Aging 2004; 25: 59.
29. Rattray M. Technology evaluation: Colostrinin, ReGen. Curr Opin Mol Ther 2005; 7: 78-84.
30. Bilikiewicz A, Gaus W. Colostrinin (a naturally occurring, pralinerich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimer's Dis 2004; 6: 17-26.
31. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-.. attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177.
32. Gilman S, Koller M, Black RS, et al. For the AN1792 (Qs-21)-201 Study Team. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562.
33. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 2003; 9: 448-452.
34. Fox NC, Black RS, Gilman S, et al. For the AN1792 (QS-21)-201 Study Team. Effects of A-beta immunotherapy (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64: 1563-1572.
35. Goldstein G.: WO2008021296A2 (2008).
36. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. Br Med J 2004; 75: 1472-1474.
37. Dodel, R., Bacher, M., Przybylski, M., Stefanescu, R., Manea, M.: WO2008084402A2 (2008).
38. Gazit, E., Cohen, T.: US20080194667 (2008).
39. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98(10): 5856-5861.
40. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 2002; 13(4): 455-459.
41. Refolo LM, Pappolla MA, Malester B, et al. Hypercholes-terolemia accelerates the Alzheimer's amyloid pathology in transgenic mouse model. Neurobiol Dis 2000; 7(4): 321-331.
42. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001; 8(5): 890-899.
43. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
44. Wolozin B, Kellman W, Rousseau P, et al. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443.
45. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer 's disease: A 26 week randomized, placebo-controlled, double -blind trial. Ann Neurol 2002; 52: 346-350.
46. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer's disease. Arch Neurol 2005; 62: 753-757.
47. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes Mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61(5): 661-666.
48. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus; A population based cohort study. Am J Epidemiol. 1997; 145(4): 301-308.
49. Hol L, Qin W, Pompl PN, et al. Diet - induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004; 18(7): 902-904.
50. Risner ME, Saunders AM, Altman JF, et al. Rosiglitazoen in Alzheimer's Disease study group. Efficacy of Rosiglitazone in a genetically defined population with mild to moderate Alzheimer's disease. Pharmacogenetics J 2006; 6(4): 246-254.
51. Lim GP, Chu T, Yang F, Beech W, Fritsch SA, Cole GM. The curry spice Curcumin reduces oxidative damage and Amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21(21): 8370-8377.